Zacks Research Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong Sell

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC dropped their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Barclays lowered their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 target price for the company. Finally, Weiss Ratings cut Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of “Hold” and an average target price of $48.71.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $21.93 on Tuesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical has a fifty-two week low of $21.43 and a fifty-two week high of $50.79. The stock has a 50 day moving average price of $25.68 and a two-hundred day moving average price of $31.38. The company has a market capitalization of $714.04 million, a P/E ratio of 17.69, a PEG ratio of 0.70 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same quarter last year, the business earned $1.68 earnings per share. The business’s revenue was up 6.3% on a year-over-year basis. Analysts expect that Collegium Pharmaceutical will post 6.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in COLL. Assetmark Inc. boosted its position in shares of Collegium Pharmaceutical by 9.3% in the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. Corient Private Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 12.2% during the 4th quarter. Corient Private Wealth LLC now owns 7,866 shares of the specialty pharmaceutical company’s stock valued at $364,000 after buying an additional 858 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 20.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock valued at $167,000 after buying an additional 861 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.